BORA PHARMACEUTICALS LTD (6472) — Cash Flow Reinvestment Rate
BORA PHARMACEUTICALS LTD (6472) has a Cash Flow Reinvestment Rate of 0.37x as of March 2026, reinvesting NT$211.08 Million (capex NT$211.08 Million ) from operating cash flow of NT$568.46 Million. Check 6472 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BORA PHARMACEUTICALS LTD Cash Flow Reinvestment Rate (2019–2025)
Historical reinvestment intensity for BORA PHARMACEUTICALS LTD across 7 annual periods. Explore debt repayment capacity of BORA PHARMACEUTICALS LTD to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year capital reinvestment analysis for BORA PHARMACEUTICALS LTD. For live market cap and broader valuation context, see BORA PHARMACEUTICALS LTD (6472) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.22x | NT$953.00 Million | NT$4.24 Billion | NT$928.67 Million | ▼ -80.2% |
| 2024 | 1.13x | NT$1.11 Billion | NT$980.81 Million | NT$687.05 Million | ▲ +254.9% |
| 2023 | 0.32x | NT$1.47 Billion | NT$4.61 Billion | NT$1.43 Billion | ▲ +22.3% |
| 2022 | 0.26x | NT$524.20 Million | NT$2.01 Billion | NT$200.22 Million | ▼ -11.3% |
| 2021 | 0.29x | NT$363.58 Million | NT$1.24 Billion | NT$363.58 Million | ▼ -65.6% |
| 2020 | 0.86x | NT$152.09 Million | NT$177.79 Million | NT$152.09 Million | ▼ -71.6% |
| 2019 | 3.01x | NT$697.33 Million | NT$231.77 Million | NT$697.33 Million | — |